Natalizumab for GVHD: too little or too late?
作者信息
Quann Kevin, Sacirbegovic Faruk, Shlomchik Warren D
机构信息
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.
出版信息
Blood Adv. 2023 Sep 12;7(17):5187-5188. doi: 10.1182/bloodadvances.2023010486.
Abstract
摘要
相似文献
1
Natalizumab for GVHD: too little or too late?
Blood Adv. 2023 Sep 12;7(17):5187-5188. doi: 10.1182/bloodadvances.2023010486.
2
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Bone Marrow Transplant. 2021 May;56(5):1006-1012. doi: 10.1038/s41409-020-01049-0. Epub 2020 Sep 8.
3
Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.
4
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Mult Scler. 2014 Aug;20(9):1269-72. doi: 10.1177/1352458514521307. Epub 2014 Feb 3.
5
Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Mult Scler Relat Disord. 2016 Sep;9:122-4. doi: 10.1016/j.msard.2016.07.012. Epub 2016 Jul 25.
6
[The case-report of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab].
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):107-109. doi: 10.17116/jnevro2018118082107.
7
Myocardial infarction in a patient with multiple sclerosis after receiving natalizumab.
Mult Scler Relat Disord. 2018 Oct;25:26-28. doi: 10.1016/j.msard.2018.07.016. Epub 2018 Jul 11.
8
Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
Mult Scler Relat Disord. 2018 Nov;26:74-76. doi: 10.1016/j.msard.2018.09.012. Epub 2018 Sep 12.
9
Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Mult Scler. 2017 Sep;23(10):1424-1427. doi: 10.1177/1352458517702533. Epub 2017 Jun 22.
10
Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use.
Mult Scler Relat Disord. 2020 May;40:101961. doi: 10.1016/j.msard.2020.101961. Epub 2020 Jan 30.
引用本文的文献
1
Identifying therapeutic targets for erectile dysfunction in the European population using genome-wide Mendelian randomization.
Sex Med. 2025 Aug 5;13(4):qfaf056. doi: 10.1093/sexmed/qfaf056. eCollection 2025 Aug.
本文引用的文献
1
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Adv. 2023 Sep 12;7(17):5189-5198. doi: 10.1182/bloodadvances.2023009853.
2
Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells.
Immunity. 2023 Feb 14;56(2):369-385.e6. doi: 10.1016/j.immuni.2023.01.003. Epub 2023 Jan 30.
3
Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
Front Immunol. 2022 Nov 11;13:1025350. doi: 10.3389/fimmu.2022.1025350. eCollection 2022.
4
'Stem-like' precursors are the fount to sustain persistent CD8 T cell responses.
Nat Immunol. 2022 Jun;23(6):836-847. doi: 10.1038/s41590-022-01219-w. Epub 2022 May 27.
5
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
Bone Marrow Transplant. 2021 Oct;56(10):2477-2488. doi: 10.1038/s41409-021-01356-0. Epub 2021 Jun 9.
6
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Blood Adv. 2019 Dec 10;3(23):4136-4146. doi: 10.1182/bloodadvances.2019000893.
7
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.
Blood Adv. 2019 Dec 10;3(23):4034-4042. doi: 10.1182/bloodadvances.2019000791.
8
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.
9
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798.
10
Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
Expert Opin Investig Drugs. 2016;25(3):263-73. doi: 10.1517/13543784.2016.1148137.
Zotero 插件